OTCQB
PHRRF

Pharmather Holdings Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Pharmather Holdings Ltd Stock Price

Vitals

Today's Low:
$0.09
Today's High:
$0.0999
Open Price:
$0.0976
52W Low:
$0.037
52W High:
$0.19
Prev. Close:
$0.101
Volume:
38897

Company Statistics

Market Cap.:
$8.94 million
Book Value:
0.08
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-27.52%
Return on Equity TTM:
-51.43%

Company Profile

Pharmather Holdings Ltd had its IPO on under the ticker symbol PHRRF.

The company operates in the Healthcare sector and Biotechnology industry. Pharmather Holdings Ltd has a staff strength of 0 employees.

Stock update

Shares of Pharmather Holdings Ltd opened at $0.1 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.09 - $0.1, and closed at $0.1.

This is a -5.35% slip from the previous day's closing price.

A total volume of 38,897 shares were traded at the close of the day’s session.

In the last one week, shares of Pharmather Holdings Ltd have slipped by -8.95%.

Pharmather Holdings Ltd's Key Ratios

Pharmather Holdings Ltd has a market cap of $8.94 million, indicating a price to book ratio of 0.5743 and a price to sales ratio of 0.

In the last 12-months Pharmather Holdings Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-4280054. The EBITDA ratio measures Pharmather Holdings Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pharmather Holdings Ltd’s operating margin was 0% while its return on assets stood at -27.52% with a return of equity of -51.43%.

In Q0.66666666666667, Pharmather Holdings Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Pharmather Holdings Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pharmather Holdings Ltd’s profitability.

Pharmather Holdings Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.6738. Its price to sales ratio in the trailing 12-months stood at 0.

Pharmather Holdings Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$7.57 million
Total Liabilities
$563258.00
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Pharmather Holdings Ltd ended 2024 with $7.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.57 million while shareholder equity stood at $7.01 million.

Pharmather Holdings Ltd ended 2024 with $0 in deferred long-term liabilities, $563258.00 in other current liabilities, in common stock, $-6190846.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.63 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Pharmather Holdings Ltd’s total current assets stands at $7.57 million while long-term investments were $0 and short-term investments were $866667.00. Its net receivables were $62235.00 compared to accounts payable of $560556.00 and inventory worth $0.

In 2024, Pharmather Holdings Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Pharmather Holdings Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.1
52-Week High
$0.19
52-Week Low
$0.037
Analyst Target Price
$

Pharmather Holdings Ltd stock is currently trading at $0.1 per share. It touched a 52-week high of $0.19 and a 52-week low of $0.19. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.12 and 200-day moving average was $0.1 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1869% of the company’s stock are held by insiders while 5.7% are held by institutions.

Frequently Asked Questions About Pharmather Holdings Ltd

The stock symbol (also called stock or share ticker) of Pharmather Holdings Ltd is PHRRF

The IPO of Pharmather Holdings Ltd took place on

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$478.8
-25.15
-4.99%
$7.28
-0.01
-0.14%
Patron Exim Ltd (PATRON)
$9.85
-0.1
-1.01%
$30.35
0.16
+0.53%
$26.52
-0.54
-2%
$10.56
0
0%
$367.8
-10.9
-2.88%
$314.75
-19.1
-5.72%
$15.03
-0.72
-4.57%
$229.65
-9.25
-3.87%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company’s product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson’s disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher’s to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

Address

82 Richmond Street East, Toronto, ON, Canada, M5C 1P1